CD19 CAR therapy for acute lymphoblastic leukemia Journal Article

  


Authors: Sadelain, M.; Brentjens, R.; Rivière, I.; Park, J.
Article Title: CD19 CAR therapy for acute lymphoblastic leukemia
Abstract: Chimeric antigen receptor (CAR) therapy is an emerging immunotherapy that shows great promise for cancer, in particular acute lymphoblastic leukemia (ALL). CARs are recombinant receptors for antigen, which, in a single molecule, redirect the specificity and function of T lymphocytes. Following their genetic transfer to patient T cells, the latter acquire the ability to recognize leukemia cells and destroy them. Several years ago, we identified CD19 as an attractive target for CAR therapy for most B cell malignancies, including ALL. We and others have reported remarkable clinical outcomes in adults and children with ALL, achieving a high complete remission rate irrespective of age, prior treatments, or other prognostic markers. Severe cytokine release may develop in patients with high tumor burdens. Several interventions are available to curb the cytokine release syndrome when it occurs. Based on the impressive results obtained with CD19 CAR therapy for ALL, it is realistic to expect that CD19 CARs will become part of the armamentarium for B cell-ALL and other B cell malignancies.
Keywords: adult; treatment outcome; immunology; lymphocyte activation; hybrid protein; recombinant fusion proteins; receptors, antigen, t-cell; precursor cell lymphoblastic leukemia-lymphoma; adoptive immunotherapy; immunotherapy, adoptive; cd19 antigen; lymphocyte antigen receptor; antigens, cd19; procedures; humans; human
Journal Title: American Society of Clinical Oncology Educational Book
Volume: 35
ISSN: 1548-8756
Publisher: American Society of Clinical Oncology  
Date Published: 2015-01-01
Start Page: e360
End Page: e363
Language: English
DOI: 10.14694/EdBook_AM.2015.35.e360
PUBMED: 25993197
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85003875622&doi=10.14694%2fEdBook_AM.2015.35.e360&partnerID=40&md5=753ceeae8b4f9e86152b7f10e1bb96fe
Notes: Review -- Export Date: 25 January 2017 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Renier J Brentjens
    286 Brentjens
  2. Jae Hong Park
    356 Park
  3. Michel W J Sadelain
    583 Sadelain
  4. Isabelle C Riviere
    240 Riviere
Related MSK Work